Synthesis, antitumor evaluation, and in silico investigation of pyridine-based pyrimidotriazine and triazolopyrimidine derivatives as potential EGFR-targeted anticancer agents.
5 affiliations
- 1Chemistry Department, Faculty of Science, Ain Shams University Cairo 11566 Egypt [email protected].
- 2Petrochemicals Department, Egyptian Petroleum Research Institute (EPRI) Cairo 11727 Egypt.
- 3Processes Design and Development Department, Egyptian Petroleum Research Institute (EPRI) Cairo 11727 Egypt.
- 4Department of Chemistry, Faculty of Science, Islamic University of Madinah Madinah 42351 Saudi Arabia [email protected].
- 5Department of Chemistry, Faculty of Science, Imam Mohammad Ibn Saud Islamic University (IMSIU) Riyadh 11623 Saudi Arabia.
Abstract
Cancer remains a major global health challenge and one of the leading causes of mortality worldwide. In the present study, a new series of fused nitrogen-containing heterocyclic derivatives was synthesized from a pyridine-based pyrimidinethione key synthon. Hydrazinolysis followed by cyclo-condensation and condensation reactions afforded structurally diverse pyrimidotriazine, triazolopyrimidine, hydrazone, and pyrazolopyrazole derivatives. The antiproliferative activities of the synthesized compounds were evaluated against human lung carcinoma (A549) and human prostate carcinoma (PC3) cell lines, with WI-38 normal human lung fibroblasts used to assess selectivity. Compounds 6 and 8 emerged as the most promising cell-based candidates, displaying the highest activities against A549 and PC3 cells, respectively, together with favorable selectivity toward cancer cells relative to WI-38 normal cells. To investigate a possible mechanism underlying the observed antiproliferative effects, the most active derivatives (6-8) were screened for EGFR kinase inhibition. Compound 7 exhibited the strongest inhibitory activity, surpassing sorafenib and revealing a clear structure-activity relationship within the series. To gain structural insight into target recognition, molecular docking studies were conducted against EGFR (PDB ID: 1M17) and cyclin-dependent kinase 2 (CDK2; PDB ID: 2A4L). The docking protocol was validated by re-docking of the corresponding co-crystallized ligands, demonstrating satisfactory reproduction of the experimental binding modes. Compounds 6-8 adopted favorable binding orientations within the ATP-binding pockets of both enzymes. Compound 7 displayed the most favorable EGFR binding profile, whereas compound 6 showed the strongest predicted affinity toward CDK2. The observed interactions emphasized the importance of molecular planarity, aromaticity, hydrogen-bonding capability, and hydrophobic contacts in stabilizing ligand-enzyme complexes. In silico ADME analysis revealed generally acceptable drug-likeness and pharmacokinetic characteristics, with compound-dependent variations in lipophilicity, gastrointestinal absorption, blood-brain barrier permeability, and P-glycoprotein recognition. Collectively, these findings identify compounds 6-8 as promising anticancer candidates, with compounds 6 and 8 representing potent and selective cell-based leads and compound 7 emerging as a promising EGFR-directed scaffold for further optimization. Furthermore, this work expands the chemical space of fused nitrogen heterocycles and provides a useful platform for the development of kinase-targeted anticancer agents.
Related
- Design, synthesis, and biological evaluation of novel 4,5-diaryl-1,2,3-thiadiazole derivatives: anticancer activity and molecular docking studies
- One-Pot Synthesis and Anticancer Activity Evaluation of Indolo[1,2-a]quinoline-7-carbonitrile Derivatives
- Design, synthesis, and biological evaluation of novel triazolopyrimidine–1,2,3-triazole–acetamide hybrids as potent α-glucosidase inhibitors supported by in silico studies
- Design and synthesis of 3-(1H-indol-3-yl)-N-(3,4,5-trimethoxyphenyl) acrylamide derivatives as anticancer agents.
- Integrated Experimental and Computational Investigation of Fluorinated Benzoylthiourea Derivatives: Structural Characterization, Hirshfeld Surface Analysis, Antioxidant Activity, and MAO–B Inhibitory Potential for Parkinson’s Disease
BibTeX
@article{ramadan2026synthesis,
title = {{Synthesis, antitumor evaluation, and in silico investigation of pyridine-based pyrimidotriazine and triazolopyrimidine derivatives as potential EGFR-targeted anticancer agents.}},
author = {Sayed K Ramadan and Ali H Abdelrahman and Mohamed A Hegazy and Ahmed Labena and Sobhi M Gomha and Magdi E A Zaki and Mohammad E Azab},
journal = {RSC advances},
year = {2026},
month = oct,
doi = {10.1039/d6ra07493f},
url = {https://europepmc.org/article/MED/42953385},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Synthesis, antitumor evaluation, and in silico investigation of pyridine-based pyrimidotriazine and triazolopyrimidine derivatives as potential EGFR-targeted anticancer agents.
AU - Sayed K Ramadan
AU - Ali H Abdelrahman
AU - Mohamed A Hegazy
AU - Ahmed Labena
AU - Sobhi M Gomha
AU - Magdi E A Zaki
AU - Mohammad E Azab
PY - 2026
DA - 2026/10/28
JO - RSC advances
DO - 10.1039/d6ra07493f
UR - https://europepmc.org/article/MED/42953385
AB - Cancer remains a major global health challenge and one of the leading causes of mortality worldwide. In the present study, a new series of fused nitrogen-containing heterocyclic derivatives was synthesized from a pyridine-based pyrimidinethione key synthon. Hydrazinolysis followed by cyclo-condensation and condensation reactions afforded structurally diverse pyrimidotriazine, triazolopyrimidine, hydrazone, and pyrazolopyrazole derivatives. The antiproliferative activities of the synthesized compounds were evaluated against human lung carcinoma (A549) and human prostate carcinoma (PC3) cell lines, with WI-38 normal human lung fibroblasts used to assess selectivity. Compounds 6 and 8 emerged as the most promising cell-based candidates, displaying the highest activities against A549 and PC3 cells, respectively, together with favorable selectivity toward cancer cells relative to WI-38 normal cells. To investigate a possible mechanism underlying the observed antiproliferative effects, the most active derivatives (6-8) were screened for EGFR kinase inhibition. Compound 7 exhibited the strongest inhibitory activity, surpassing sorafenib and revealing a clear structure-activity relationship within the series. To gain structural insight into target recognition, molecular docking studies were conducted against EGFR (PDB ID: 1M17) and cyclin-dependent kinase 2 (CDK2; PDB ID: 2A4L). The docking protocol was validated by re-docking of the corresponding co-crystallized ligands, demonstrating satisfactory reproduction of the experimental binding modes. Compounds 6-8 adopted favorable binding orientations within the ATP-binding pockets of both enzymes. Compound 7 displayed the most favorable EGFR binding profile, whereas compound 6 showed the strongest predicted affinity toward CDK2. The observed interactions emphasized the importance of molecular planarity, aromaticity, hydrogen-bonding capability, and hydrophobic contacts in stabilizing ligand-enzyme complexes. In silico ADME analysis revealed generally acceptable drug-likeness and pharmacokinetic characteristics, with compound-dependent variations in lipophilicity, gastrointestinal absorption, blood-brain barrier permeability, and P-glycoprotein recognition. Collectively, these findings identify compounds 6-8 as promising anticancer candidates, with compounds 6 and 8 representing potent and selective cell-based leads and compound 7 emerging as a promising EGFR-directed scaffold for further optimization. Furthermore, this work expands the chemical space of fused nitrogen heterocycles and provides a useful platform for the development of kinase-targeted anticancer agents.
SN - 2046-2069
ER -